Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label single-arm RE-021 in Japanese IgA nephropathy
jRCT2051240070Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sparsentan in IgA nephropathy (IgAN), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in urinary protein-to-creatinine ratio (UP/C) based on 24-hour urine samples at Week 36. Started Jul 2024; status: active, not recruiting.
02
Drugs
sparsentan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on jRCT2051240070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240070.